Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Philippe Gui
Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Evolution of metastasis: new tools and insights
Highlights Metastasis arises following evolutionary events during which cancer cells acquire the ability to escape from the tumor, disseminate, and seed distant organs. Challenges in characterizing the spatial and temporal progression of metastasis have restricted our understanding of drivers of malignancy, reflected by a lack of therapeutic solutions.
Stepwise evolution of therapy resistance in AML
Relapse of AML patients to FLT3i treatment is the result of a long-term and stepwise process leading to resistance, whereby residual cancer cells initially survive and subsequently expand. Here, Joshi et al. use a multifaceted approach to characterize how microenvironment-driven early resistance to gilteritinib evolves into mutation-driven late resistance.
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Highlights • scRNA-seq is feasible in metastatic human NSCLCs and reveals a rich tumor ecosystem • Individual tumors and cancer cells exhibit substantial molecular diversity • Cancer and tumor microenvironment cells exhibit marked therapy-induced plasticity • scRNA-seq of metastatic NSCLCs unveils new opportunities to improve clinical outcomes Summary Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables adaptability, limits therapeutic success, and remains...
Co-occurring genetic alterations in the RAS pathway promote resistance to MET inhibitor treatment in non-small cell lung cancer with a MET exon 14 skipping mutation
Co-occurring genetic alterations in the RAS pathway promote resistance to MET inhibitor treatment in non-small cell lung cancer with a MET exon 14 skipping mutation Julia K Rotow, Philippe Gui, Wei Wu, Victoria M Raymond, Richard B Lanman, Frederic J Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B Corcoran, Iwei Yeh, Boris C Bastian, Petr Starostik, Kimberly Newsom, Victor R Olivas, Alexander M Wolff, James S Fraser, Eric A Collisson, Caroline E McCoach, Collin M Blakely,...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Philippe
Contact Philippe, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack